FDA reportedly eyeing staff bonuses to accelerate drug reviews
Source: SeekingAlpha
2026-02-26 13:35:52 ET
More on leading drugmakers
- Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
- Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade)
- Merck: Why Investors Should Remain Bullish Despite Patent Risks
- Kenvue effort to dismiss Tylenol case rejected by Texas judge
- CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
Read the full article on Seeking Alpha
For further details see:
FDA reportedly eyeing staff bonuses to accelerate drug reviews
Merck & Company Inc.
NASDAQ: MRK
MRK Trading
-1.26% G/L:
$119.53 Last:
2,047,248 Volume:
$120.37 Open:
MRK Latest News
April 02, 2026 06:50:00 am
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
April 02, 2026 06:45:00 am
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ?1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
April 01, 2026 07:00:00 am
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
MRK Stock Data
$291,612,827,755
2,457,202,311
0.02%
2165
N/A
Pharmaceuticals
Healthcare
US
Rahway
